A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma

Acta Pharmacologica Sinica

Volumn 32, Issue 4, 2011, Pages 537-542

  Lin, Yu Hsiang ^a   Chen, Chien Lun ^a,b   Hou, Chen Pang ^a   Chang, Phei Lang ^a,b   Tsui, Ke Hung ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

androgen; luteinizing hormone releasing hormone (LHRH); medical castration; metastasis; prognosis; prostate neoplasm; prostate specific antigen; surgical castration

Indexed keywords

BICALUTAMIDE; CYPROTERONE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER STAGING; CASTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CARCINOMA; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANDROGENS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 79953768586     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.236     Document Type: Article

References (36)

1. Stamey T, Yang N, Hay A, McNeal J, Freiha F, Redwine E. Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16. (Pubitemid 17147932)
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specifi c antigen. Invest Urol 1979; 17: 159-63. (Pubitemid 10132507)
3. Loblaw DA, Virgo KS, Nam R, Somerfi eld MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. J Clin Oncol 2007; 25: 1596-605. (Pubitemid 46733088)
4. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
5. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008; 53: 941-9.
6. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76. (Pubitemid 46638985)
7. Anderson J, Abrahamsson PA, Crawford D, Miller K, Tombal B. Manage ment of advanced prostate cancer: can we improve on androgen deprivation therapy? BJU Int 2008; 101: 1497-501. (Pubitemid 351704035)
8. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998-2006.
9. Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. The Prostate 1983; 4: 579-94. (Pubitemid 14243323)
10. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76. (Pubitemid 34787603)
11. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without fl utamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42. (Pubitemid 28457865)
12. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927-41. (Pubitemid 41079913)
13. Weight CJ, Klein EA, Jones JS. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the US medicare population. Cancer 2008; 112: 2195-201. (Pubitemid 351628629)
14. Chodak GW. Is the increase in orchiectomy for prostate cancer patients appropriate? Cancer 2008; 112: 2106-7. (Pubitemid 351628617)
15. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int 2006; 77: 135-8. (Pubitemid 44195773)
16. Kaisary AV, Tyrrell CJ, Peeling WB, Griffi ths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8.
17. Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58: 5-9.
18. de Reijke T, Derobert E. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a fi nal update. Eur Urol 2002; 42: 139-46.
19. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006; 24: 1868-76. (Pubitemid 46638985)
20. Chuang CK, Chu SH, Chiang YJ, Chun-Te Wu M, Lin MH, Wei TY, et al. Tolerability assessment of maximal androgen blockade with 50 mg daily of bicalutamide and castration in patients with advanced prostate cancer. Chang Gung Med J 2002; 25: 577-82.
21. Albertsen P. Androgen deprivation in prostate cancer-step by step. N Engl J Med 2009; 360: 2572-4.
22. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24. (Pubitemid 40490022)
23. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specifi c antigen testing: a population-based cohort study. BJU Int 2006; 98: 973-8. (Pubitemid 44536442)
24. Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol 2009; 56: 609-16.
25. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81. (Pubitemid 351969301)
26. Diblasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, et al. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. BJU Int 2009; 104: 1208-14.
27. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int 2008; 101: 1077-83. (Pubitemid 351502653)
28. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-9. (Pubitemid 43779173)
29. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-8.
30. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300. (Pubitemid 27318990)
31. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821-7. (Pubitemid 39079668)
32. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgendependent growth. Eur Urol 2009; 55: 310-20.
33. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000; 164: 726-9. (Pubitemid 30637611)
34. Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006; 49: 54-8; discussion 58. (Pubitemid 41789955)
35. Tombal B. The importance of testosterone control in prostate cancer. Eur Urol Suppl 2007; 6: 834-9. (Pubitemid 47102240)
36. Tombal B, Berges R. How good do current lhrh agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4: 30-6. (Pubitemid 41423590)